{'52WeekChange': -0.31191224,
 'SandP52WeekChange': None,
 'address1': '7575 Gateway Boulevard',
 'address2': 'Suite 110',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.25,
 'askSize': 3000,
 'averageDailyVolume10Day': 6717962,
 'averageVolume': 4114677,
 'averageVolume10days': 6717962,
 'beta': 1.40168,
 'beta3Year': None,
 'bid': 4.2,
 'bidSize': 1800,
 'bookValue': 2.541,
 'category': None,
 'circulatingSupply': None,
 'city': 'Newark',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.35,
 'dayLow': 4.07,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.265,
 'enterpriseToRevenue': None,
 'enterpriseValue': 116505976,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '510-293-9090',
 'fiftyDayAverage': 3.6817143,
 'fiftyTwoWeekHigh': 6.56,
 'fiftyTwoWeekLow': 1.21,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 55546126,
 'forwardEps': -0.98,
 'forwardPE': -4.3061223,
 'fromCurrency': None,
 'fullTimeEmployees': 36,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00617,
 'heldPercentInstitutions': 0.88007003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/cymabay.com',
 'longBusinessSummary': 'CymaBay Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on developing and '
                        'providing therapies to treat liver and other chronic '
                        'diseases. Its lead product candidate is seladelpar '
                        '(MBX-8025), a selective agonist of peroxisome '
                        'proliferator activated receptor delta, which has '
                        'completed Phase II clinical study for the treatments '
                        'of primary biliary cholangitis and sclerosing '
                        'cholangitis, as well as patients with nonalcoholic '
                        'steatohepatitis. The company also develops MBX-2982, '
                        'a selective orally-active G protein-coupled receptor '
                        'agonist that interacts with bioactive lipids known to '
                        'stimulate glucose-dependent insulin secretion for the '
                        'treatment of gut/liver disease. Its preclinical stage '
                        'product candidate is CB-001, a G protein-coupled '
                        'receptor for omega-3 fatty acids, such as '
                        'docosahexaenoic acid for the treatment of gut/liver '
                        'disease. It has development and licensing agreement '
                        'with Janssen Pharmaceuticals, Inc. to develop and '
                        'discover undisclosed metabolic disease target '
                        'agonists for the treatment of type 2 diabetes and '
                        'other disorders; and a license agreement with DiaTex, '
                        'Inc. to develop and commercialize therapeutic '
                        'products comprising halofenate and its enantiomers, '
                        'derivatives, and analogs for the treatment of '
                        'diseases. The company was formerly known as '
                        'Metabolex, Inc. CymaBay Therapeutics, Inc. was '
                        'incorporated in 1988 and is headquartered in Newark, '
                        'California.',
 'longName': 'CymaBay Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 290684128,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_31424',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -92821000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.3098,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '510-293-8800',
 'previousClose': 4.39,
 'priceHint': 4,
 'priceToBook': 1.6607635,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.35,
 'regularMarketDayLow': 4.07,
 'regularMarketOpen': 4.3098,
 'regularMarketPreviousClose': 4.39,
 'regularMarketPrice': 4.3098,
 'regularMarketVolume': 3835130,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 68882496,
 'sharesPercentSharesOut': 0.1173,
 'sharesShort': 8077762,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8876550,
 'shortName': 'CymaBay Therapeutics Inc.',
 'shortPercentOfFloat': 0.1177,
 'shortRatio': 4.69,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'CBAY',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.35,
 'twoHundredDayAverage': 2.4555037,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'a8ce2162-5d9e-34db-a343-001f7cebee58',
 'volume': 3835130,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.cymabay.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94560'}